Neurology Today editor-in-chief to deliver Taubman Institute's visiting professor lecture Sept. 6

Steven P. Ringel, M.D., editor-in-chief of Neurology Today, will deliver the Taubman Institute's Visiting Professor Lecture at noon on Sept. 6 in Ann Arbor.

Dr. Ringel is Professor of Neurology and Vice President for Clinical Effectiveness and Patient Safety at the University of Colorado Hospital (UCH). He has authored numerous articles and four books covering a broad range of issues in research, patient care, health policy,and patterns of practice. He is the founding editor of Current Treatment in Neurology and the current Editor-in-Chief of Neurology Today. He is past president of the American Academy of Neurology (AAN) and of the medical staff of UCH.

Dr. Ringel's current investigative activities emphasize quality and safety initiatives, cost effectiveness analysis and community database development. He has directed the Neuromuscular Section of the University of Colorado School of Medicine since 1976. He continues to have a busy neuromuscular practice and is actively involved in multi-university studies to evaluate drug efficacy in amyotrophic lateral sclerosis.

An honors graduate of the University of Michigan Medical School, Dr. Ringel completed his neurology residency at Rush-Presbyterian-St. Luke's Medical Center in Chicago and a post-doctoral research fellowship at the National Institutes of Health. He completed a Robert Wood Johnson Health Policy Fellowship and served as an Institute of Medicine Scholar-in-Residence working as Senator Jay Rockefeller's health policy aide during the 1992 Congressional session.

Dr. Ringel's lecture is entitled "Academic hospitals: the imperative for performance improvement," and is presented jointly with the Department of Internal Medicine's Grand Rounds program.  The talk is scheduled for noon - 1 p.m. in the Ford Auditorium at the University of Michigan Hospital.

CME credit for physicians is available. 

 


Help Us Make A Difference. Make A Donation That Could Save Lives.

Make A Gift

Connect/
Share/
follow/

Follow Us / Friend Us

Discovery-driven research that matters

phallodin

Taubman Scholar Dr. Charles Burant tests promising diabetes drug

TAK-875, a new treatment for type 2 diabetes, improves blood sugar control and is equally effective as glimepiride, but has a significantly lower risk of creating a dangerous drop in blood sugar, called hypoglycemia, according to a new study.

Read more

Taubman Institute leaders make the case for more doctor-scientist funding

 

The prestigious "Academic Medicine" journal has just published a new article authored by Taubman Institute senior management and Detroit-area attorney Scott Roberts.

The article explores the problematic gap between bench research and clinical application of new treatments or cures. 

Read more


Help Us Make A Difference. Make A Gift.

Leaders from the realms of business, academia and the community help to refine the Taubman Institute's vision, to monitor progress and to provide support, advice and counsel.

Meet the Leadership Advisory Board

Meet the Scientific Advisory Board

About Taubman Institute Video

In this video feature, Taubman Scholars explain why funding for high-risk research is so important to their work and to the discovery of promising cures and treatments.  

 

Stem cell surgery targets ALS Video

Patients glean hope from trial’s progress but wish it were faster

 

video-emerging-scholars-programDonors pitch in to keep brilliant science minds at U-M Video

Emerging Scholars program connects promising M.D.-researchers with philanthropists